DAPAGLIFLOZIN AND SAXAGLIPTIN

FDA Drug Profile — DAPAGLIFLOZIN AND SAXAGLIPTIN

Drug Details

Generic Name
DAPAGLIFLOZIN AND SAXAGLIPTIN
Brand Names
DAPAGLIFLOZIN AND SAXAGLIPTIN
Application Number
ANDA211533
Sponsor
Novadoz Pharmaceuticals LLC
NDC Codes
1
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
DAPAGLIFLOZIN, SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE

Indications and Usage

1 INDICATIONS AND USAGE Dapagliflozin and saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Dapagliflozin and saxagliptin tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [ see WARNINGS AND PRECAUTIONS (5.1) ]. Dapagliflozin and saxagliptin tablets is a combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor and saxagliptin a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 )